If you have been NEWLY DIAGNOSED START HERE
In this seventh video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the lunchtime Lung Cancer Champion Award, presented to Chris Draft by GRACE founder, H. Jack West.
Our sixth video is from the forum breakout session for EGFR patients and caregivers, featuring co-chairs Dr. Greg Riely and Dr. Jack West, and patient moderator Bob Fuerst.
Our fifth video from the Targeted Therapies in Lung Cancer Patient Forum, filmed in Aurora Colorado on August 20, 2016 is the second part of the forum breakout session for ROS1 patients and caregivers, featuring co-chairs Dr. Ross Camidge and Dr. Caroline McCoach, and patient moderator Tori Tomalia.
Our fourth video from the Targeted Therapies in Lung Cancer Patient Forum, filmed in Aurora Colorado on August 20, 2016 is the first part of the forum breakout session for ROS1 patients and caregivers, featuring co-chairs Dr. Ross Camidge and Dr. Caroline McCoach, and patient moderator Tori Tomalia.
Our third video from the Targeted Therapies in Lung Cancer Patient Forum, filmed in Aurora Colorado on August 20, 2016, is the second part of the forum breakout session for ALK + patients and caregivers, featuring Dr. Shirish Gadgeel and patient moderator Linnea Olson.
Probably the most immediate potentially practice-changing presentation from ASCO was the Japanese J-ALEX study in the subset of about 4-5% of patients...
Probably the most immediate potentially practice-changing presentation from ASCO was the Japanese J-ALEX study in the subset of about 4-5% of patients...
It seemed inevitable, I think. Several immuntherapy agents known as PD-1 or PD-L1 checkpoint inhibitors have been shown to lead to better survival...
After completing my unpacking from ASCO and beginning to see a path of light as I dig out from under the backup of work that accumulated, I wanted to...
For patients with an activating EGFR mutation and who develop “acquired resistance”, the pattern of progression that occurs after a sometimes long...
It is as if my mom's digestive system is now paralyzed. No one seems to know what to do or how to give her relief from the nausea and discomfort, or...
Dear Team, my mother had breast cancer 5 yrs back.compleyed surgery of breast removal and had harmone therapy for 5 yrs and recently diagnosed with...
Hello GRACE members, To post a new question in the forums, click on "Participate" in the menu bar near the top of the page. When the new page appears...
Mother-in-Law was diagnosed with NSCLC and after a blood biopsy, doctor is recommending Osimertinib. I tried searching on the main page, but it wasn't...
My mum's oncologist decided that the next line of the treatment for my mum will be carboplatin monotherapy. The reason for carboplatin alone and not...
Even in the world of lung cancer, there are things to be grateful for. This November, join GRACE as we celebrate them with doctors, patients and caregivers.
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early stage NSCLC.
Dr. Eddie Garon from UCLA Medical Center reviews the general mechanism of action of immune checkpoint inhibitors and how they can be an effective therapy in lung cancer.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Dr. Greg Riely from MSKCC provides an introduction to the epidermal growth factor receptor (EGFR), what an EGFR mutation means, and which patients are more likely to have them.
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock